摘要
目的观察伊立替康联合替吉奥与伊立替康联合雷替曲塞治疗晚期胃癌的临床疗效及安全性。方法根据二线化疗方案将80例晚期胃癌患者分为观察组(n=42)和对照组(n=3 8),观察组患者接受替吉奥联合伊立替康治疗,对照组患者接受雷替曲塞联合伊立替康治疗。比较两组患者近期疗效、随访1年的生存情况及不良反应发生情况,并分析化疗疗效与患者临床特征的关系。结果观察组患者客观有效率(ORR)、疾病控制率(DCR)分别为57.14%、76.19%,均高于对照组的34.21%、52.63%,差异均有统计学意义(P<0.05)。不同性别、年龄、美国东部肿瘤协助组(ECOG)体力状况(PS)评分、病理类型、原发部位晚期胃癌患者的化疗疗效比较,差异均无统计学意义(P> 0.05);分化程度为低分化、转移部位仅有1个的晚期胃癌患者的化疗疗效优于对照组患者,差异均有统计学意义(P <0.05)。随访1年,观察组患者中位无进展生存时间为6.51个月,长于对照组患者的4.3 5个月,差异有统计学意义(P <0.05)。两组不良反应主要为1~2级,均无4级不良反应,两组患者各不良反应发生率比较,差异均无统计学意义(P> 0.05)。结论伊立替康联合替吉奥治疗晚期胃癌的临床疗效优于伊立替康联合雷替曲塞,可提高患者的近期疗效及无进展生存时间,且不良反应可控,安全性较高。
Objective To observe the clinical efficacy and safety of irinotecan combined with tigio and irinotecan combined with raltitrexed in the treatment of advanced gastric cancer.Method According to second-line chemotherapy,80 patients with advanced gastric cancer were divided into observation group(n=42)and control group(n=38).Patients in the observation group were treated with tigio combined with irinotecan,while patients in the control group were treated with raltitrexed and irinotecan.The short-term curative effect,1-year survival rate and adverse reactions were compared between the two groups,and analyze the relationship between chemotherapy efficacy and clinical characteristics.Result The observation group had higher objective effective rate(ORR)and disease control rate(DCR)than the control group(57.14%vs 34.21%and 76.19%vs 52.63%,respectively)(P<0.05).There were no significant differences in gender,age,ECOG PS score,pathological type and primary site of advanced gastric cancer patients(P>0.05).The chemotherapy efficacy of patients with advanced gastric cancer with low differentiation and only one metastasis site was better than that of the control group(P<0.05).After 1 year of follow-up,the median progression-free survival time of the observation group was 6.51 months,which was longer than 4.35 months of the control group,and the difference was statistically significant(P<0.05).The main adverse reactions of the two groups were grade 1 to grade 2,no grade 4 adverse reaction was found,and there was no significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion For patients with advanced gastric cancer who failed in first-line standardized treatment,irinotecan combined with tigio would produce better short-term efficacy and progression-free survival time than that of irinotecan combined with raltitrexed,and the adverse reactions were tolerable.
作者
雒雷鸣
赵伟峰
张永喜
LUO Leiming;ZHAO Weifeng;ZHANG Yongxi(Department of Pharmacy,the Third Affiliated Hospital of Xinxiang Medical College,Xinxiang 453003,He’nan,China;Department of Infectious Diseases,the Third Affiliated Hospital of Xinxiang Medical College,Xinxiang 453003,He’nan,China;Department of Oncology,the Third Affiliated Hospital of Xinxiang Medical College,Xinxiang 453003,He’nan,China)
出处
《癌症进展》
2020年第23期2431-2434,共4页
Oncology Progress
关键词
伊立替康
替吉奥
雷替曲塞
晚期胃癌
生存分析
irinotecan
tigio
raltitrexed
advanced gastric cancer
survival analysis
